A comparative study on serum S100B protein levels between chronic schizophrenic patients with and without tardive dyskinesia.

WANG Ning,TAN Yunlong,YANG Fude,WANG Zhiren,LI Jia,ZHENG Lili,ZHOU Dongfeng
2011-01-01
Abstract:Objective To investigate the role of S100B protein in the pathophysiology of tardive dyskinesia(TD) by analyzing the serum levels of S100B in schizophrenic patients with and without TD.Methods The serum S100B levels were examined by using enzyme-linked immuno-sorbent assay(ELSIA)in 95 schizophrenic patients with(TD group,n = 40)and without(non-TD group,n = 55) TD and 40 healthy volunteers(control group).The serum S100B levels were compared among the three groups.Psychopathological symptoms were assessed by using the positive and negative syndrome scale(PANSS) and the severity of TD was evaluated using abnormal involuntary movement scale(AIMS).Results There were significant differences in the serum S100B levels among TD [(0.17 ± 0.04)μg/L],non-TD[(0.15 ± 0.02)μg/L] and control [(0.10 ± 0.03)μg/L] groups(F = 53.07,P < 0.01).The S100B levels in patients with TD or without TD were significantly higher compared with controls(P < 0.01).Moreover,the serum S100B levels in TD group were significantly higher than those in non-TD group(P < 0.01).The serum S100B levels markedly correlated with the total score of AIMS(r = 0.52,P < 0.01) in the TD group.Conclusion The serum levels of S100B in patients with TD are significantly increased,which is positively correlated with the total score of AIMS,indicating dysfunction of glia cell might play key roles in pathophysiological mechanisms of TD.
What problem does this paper attempt to address?